Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating on February 20.
David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s potential for sustained revenue growth. One key reason is the underestimated value and longevity of the royalties Sanofi will receive from Alnylam’s Amvuttra sales. The recent announcement that Alnylam’s next-generation drug, nucresiran, will not be approved until around 2030 is beneficial for Sanofi, as it extends the period during which Sanofi will earn royalties from Amvuttra.
Additionally, the delay in nucresiran’s approval means that Sanofi can continue to benefit from Amvuttra’s market presence without the competition of a royalty-free alternative. Alnylam’s decision to pursue a longer, outcomes-based trial for nucresiran, similar to Amvuttra’s HELIOS-B, further supports this extended timeline. As a result, Sanofi is expected to maintain a strong revenue stream from Amvuttra royalties, which significantly contributes to its financial outlook and justifies the Buy rating.
In another report released on February 20, Bernstein also maintained a Buy rating on the stock with a €114.00 price target.